

Breast Cancer Extended Endocrine Therapy Algorithmic Tests

- I. The use of the breast cancer extended endocrine therapy test Breast Cancer Index (BCI) is considered **medically necessary** when:
 - A. The member is female (sex assigned at birth), **AND**
 - B. The member has primary breast cancer that is ductal/NST, lobular, mixed or micropapillary, **AND**
 - C. The member's tumor is hormone receptor-positive (estrogen receptor-positive or progesterone receptor-positive), **AND**
 - D. The member's tumor is human epidermal growth factor receptor 2 (HER2)-negative, **AND**
 - E. The member has no distant metastases, **AND**
 - F. The member has completed at least 4 years of endocrine therapy, **AND**
 - G. The member is considering extended treatment with adjuvant therapy (e.g., tamoxifen, aromatase inhibitors, immunotherapy), **AND**
 - H. The member meets one of the following (regardless of menopausal status):
 1. Tumor is greater than 0.5 cm and node negative (pN0), **OR**
 2. Lymph nodes are pN1mi (2mm or smaller axillary node metastases), **OR**
 3. Lymph nodes are pN1 (1-3 positive nodes).
- II. The use of the breast cancer extended endocrine therapy test Breast Cancer Index (BCI) in men (sex assigned at birth) with breast cancer is considered **investigational**.
- III. The use of the breast cancer extended endocrine therapy test Breast Cancer Index (BCI) is considered **investigational** for all other indications.

DEFINITIONS

1. **Adjuvant** therapy is a medication (such as chemotherapy or endocrine therapy) given after the surgical removal of a cancerous tumor.
2. **Ductal/NST** is a ductal breast cancer of no special type (NST), meaning the cancer cells have no features that classify them as a specific type of breast cancer when examined by microscope.

REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 6.2024.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
2. Andre F, Ismaila N, Allison KH, et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update [published correction appears in J Clin Oncol. 2022 Aug 1;40(22):2514]. *J Clin Oncol*. 2022;40(16):1816-1837. doi:10.1200/JCO.22.00069